|
시장보고서
상품코드
1671137
세계의 혈액암 치료제 시장 규모, 점유율, 동향, 업계 분석 : 질환별, 치료법별, 최종 용도별, 지역별 - 시장 예측(2025-2034년)Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Therapy, End Use, and Region - Market Forecast, 2025-2034 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Polaris Market Research의 최신 조사에 따르면, 혈액암 치료제 시장 규모는 2034년까지 1,481억 5,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.
혈액암 치료제는 백혈병, 림프종, 골수종 등 혈액암을 관리하는 데 사용되는 치료법을 말합니다. 이들 암은 혈액, 골수, 림프계, 비장에 영향을 미치며, 전문적인 치료 접근이 필요합니다. 백혈병, 림프종, 골수종과 같은 혈액암의 발병률 증가와 치료 옵션의 발전에 힘입어 혈액암 치료제 시장 점유율이 크게 성장하고 있습니다. 주요 촉진요인으로는 CAR-T 세포 치료제, 단클론항체 등 면역치료제의 부상과 부작용이 적고 보다 정확한 치료를 제공하는 표적 치료제의 채택 확대가 꼽힙니다. 또한, 병용요법 개발, 맞춤의료, 바이오시밀러의 확대 등 기존 치료법을 대체할 수 있는 비용 효율적인 치료법에 대한 비즈니스 기회도 창출되고 있습니다. 또한, 현재 진행 중인 연구, 임상시험, 새로운 치료법에 대한 규제 당국의 승인은 시장의 기술 혁신을 지속적으로 촉진하고 있습니다. 외래 치료로의 전환을 통한 환자 접근성 향상, 치료 저항성 감소에 대한 노력은 전체 시장 확대에 기여하고 있으며, 향후 몇 년 동안 지속적인 성장이 예상됩니다.
혈액암 치료제 시장 : 분석 개요
백혈병은 만성 림프성 백혈병(CLL), 급성 골수성 백혈병(AML) 등 질환의 높은 유병률로 인해 시장 점유율 1위를 차지하고 있습니다. 표적 치료제 개발이 크게 진전되면서 성장을 견인하고 있습니다. 그러나 림프종은 CAR-T 세포 치료와 같은 면역요법의 채택 증가로 인해 가장 빠르게 성장하는 분야입니다.
면역치료는 혈액암 치료제 시장에서 가장 큰 점유율을 차지하고 있으며, CAR-T 세포 치료와 단클론항체가 혈액암 치료의 변화에 중요한 역할을 하고 있습니다. 정밀치료가 혈액암 환자의 예후를 개선하고 부작용을 감소시키면서 표적 치료제가 가장 빠른 성장세를 보이고 있습니다.
병원 약국은 CAR-T 세포 치료, 화학요법 등 복잡한 치료법을 시행하는 데 있어 핵심적인 역할을 수행하기 때문에 가장 큰 시장 점유율을 차지하고 있습니다. 소매 약국은 경구용 항암제 및 재택 치료 옵션에 대한 수요 증가에 힘입어 가장 빠르게 성장하고 있는 분야입니다.
북미는 높은 치료 접근성, 선진화된 의료 인프라, 새로운 치료법에 대한 규제적 지원으로 시장을 주도하고 있습니다. 아시아태평양은 암 발병률 증가, 의료 접근성 향상, 치료 혁신에 대한 투자로 인해 가장 빠르게 성장하고 있는 지역입니다.
목차
제1장 소개
제2장 주요 요약
제3장 분석 방법
제4장 혈액암 치료제 시장 인사이트
- 시장 현황
- 혈액암 치료제 시장 역학
- 성장 촉진요인과 기회
- AI와 머신러닝의 통합
- 고처리량 실험으로의 전환
- 성장 억제요인과 과제
- 데이터 용량 부족
- 성장 촉진요인과 기회
- PESTLE 분석
- 혈액암 치료제 시장 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 혈액암 치료제 시장 : 질환별
- 주요 분석 결과
- 소개
- 백혈병
- 림프종
- 골수종
제6장 세계의 혈액암 치료제 시장 : 치료법별
- 주요 분석 결과
- 소개
- 화학요법
- 면역요법
- 표적요법
- 기타
제7장 세계의 혈액암 치료제 시장 : 최종 용도별
- 주요 분석 결과
- 소개
- 병원 약국
- 기타
제8장 세계의 혈액암 치료제 시장 : 지역별
- 주요 분석 결과
- 소개
- 혈액암 치료제 시장 평가 : 지역별(2020-2034년)
- 북미
- 북미 : 질병별(2020-2034년)
- 북미 : 치료법별(2020-2034년)
- 북미 : 최종 용도별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 질병별(2020-2034년)
- 유럽 : 치료법별(2020-2034년)
- 유럽 : 최종 용도별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 질병별(2020-2034년)
- 아시아태평양 : 치료법별(2020-2034년)
- 아시아태평양 : 최종 용도별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 질병별(2020-2034년)
- 중동 및 아프리카 : 치료법별(2020-2034년)
- 중동 및 아프리카 : 최종 용도별(2020-2034년)
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 질병별(2020-2034년)
- 라틴아메리카 : 치료법별(2020-2034년)
- 라틴아메리카 : 최종 용도별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제9장 경쟁 구도
- 사업 확대·기업 인수 분석
- 사업 확대
- 기업 인수
- 제휴/협업/합의/공개
제10장 기업 개요
- AbbVie Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- Johnson & Johnson
- Novartis AG
- Pfizer Inc.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- BeiGene
- Kite Pharma(a subsidiary of Gilead Sciences)
- Celgene Corporation(acquired by Bristol-Myers Squibb)
- Regeneron Pharmaceuticals, Inc.
The hematologic malignancies therapeutics market size is expected to reach USD 148.15 billion by 2034, according to a new study by Polaris Market Research. The report "Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease (Leukemia, Lymphoma, and Myeloma), Therapy, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Hematologic malignancies therapeutics refer to the medical treatments used to manage blood cancers, which include leukemia, lymphoma, and myeloma. These cancers affect the blood, bone marrow, lymphatic system, or spleen and require specialized therapeutic approaches. The hematologic malignancies therapeutics market share is experiencing significant growth, driven by increasing incidence rates of blood cancers such as leukemia, lymphoma, and myeloma, alongside advancements in treatment options. Key drivers include the rise of immunotherapies, such as CAR-T cell therapies and monoclonal antibodies, as well as the growing adoption of targeted therapies that offer more precise treatment with fewer side effects. Opportunities are emerging in the development of combination therapies, personalized medicine, and the expansion of biosimilars, providing cost-effective alternatives to traditional treatments. Additionally, ongoing research, clinical trials, and regulatory approvals for new therapies continue to drive innovation in the market. Trends such as a shift toward outpatient care increased patient access, and a focus on reducing treatment resistance contribute to the market's overall expansion, positioning it for continued growth in the coming years.
Hematologic Malignancies Therapeutics Market Report Highlights
Leukemia dominates the market in terms of market share due to the high prevalence of conditions such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Significant advancements in targeted therapies are driving its growth. However, lymphoma is the fastest growing segment, driven by the increasing adoption of immunotherapies such as CAR-T cell therapies.
Immunotherapy holds the largest hematologic malignancies therapeutics market share, with CAR-T cell therapies and monoclonal antibodies playing a crucial role in transforming the treatment of hematologic malignancies. Targeted therapies are registering the fastest growth as precision treatments continue to improve outcomes and reduce side effects in blood cancer patients.
Hospital pharmacies hold the largest market share due to their central role in administering complex treatments such as CAR-T cell therapies and chemotherapy. Retail pharmacies are the fastest growing segment, supported by the rising demand for oral oncolytics and at-home treatment options.
North America dominates the market due to high treatment accessibility, advanced healthcare infrastructure, and regulatory support for new therapies. Asia Pacific is the fastest growing region, fueled by increasing cancer incidence, improving healthcare access, and investment in treatment innovations.
Polaris Market Research has segmented the hematologic malignancies therapeutics market report based on disease, therapy, end use, and region:
By Disease Outlook (Revenue-USD Billion, 2020 - 2034)
- Leukemia
- Lymphoma
- Myeloma
By Therapy Outlook (Revenue-USD Billion, 2020 - 2034)
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Others
By End Use Outlook (Revenue-USD Billion, 2020 - 2034)
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Regional Outlook (Revenue-USD Billion, 2020 - 2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source
4. Global Hematologic Malignancies Therapeutics Market Insights
- 4.1. Hematologic Malignancies Therapeutics Market - Market Snapshot
- 4.2. Hematologic Malignancies Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Integration of AI and Machine Learning
- 4.2.1.2. Shift Toward High-Throughput Experimentation
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Insufficient data volume
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Hematologic Malignancies Therapeutics Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Hematologic Malignancies Therapeutics Market, by Disease
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 5.3. Leukemia
- 5.3.1. Global Hematologic Malignancies Therapeutics Market, by Leukemia, by Region, 2020-2034 (USD Billion)
- 5.4. Lymphoma
- 5.4.1. Global Hematologic Malignancies Therapeutics Market, by Lymphoma, by Region, 2020-2034 (USD Billion)
- 5.5. Myeloma
- 5.5.1. Global Hematologic Malignancies Therapeutics Market, by Myeloma, by Region, 2020-2034 (USD Billion)
6. Global Hematologic Malignancies Therapeutics Market, by Therapy
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 6.3. Chemotherapy
- 6.3.1. Global Hematologic Malignancies Therapeutics Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
- 6.4. Immunotherapy
- 6.4.1. Global Hematologic Malignancies Therapeutics Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
- 6.5. Targeted Therapy
- 6.5.1. Global Hematologic Malignancies Therapeutics Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
- 6.6. Others
- 6.6.1. Global Hematologic Malignancies Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)
7. Global Hematologic Malignancies Therapeutics Market, by End Use
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 7.3. Hospital Pharmacies
- 7.3.1. Global Hematologic Malignancies Therapeutics Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
- 7.4. Others
- 7.4.1. Global Hematologic Malignancies Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)
8. Global Hematologic Malignancies Therapeutics Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Hematologic Malignancies Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
- 8.3. Hematologic Malignancies Therapeutics Market - North America
- 8.3.1. North America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.3.2. North America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.3.3. North America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.3.4. Hematologic Malignancies Therapeutics Market - U.S.
- 8.3.4.1. U.S.: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.3.4.2. U.S.: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.3.4.3. U.S.: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.3.5. Hematologic Malignancies Therapeutics Market - Canada
- 8.3.5.1. Canada: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.3.5.2. Canada: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.3.5.3. Canada: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4. Hematologic Malignancies Therapeutics Market - Europe
- 8.4.1. Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.4.2. Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.4.3. Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.4. Hematologic Malignancies Therapeutics Market - UK
- 8.4.4.1. UK: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.4.4.2. UK: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.4.4.3. UK: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.5. Hematologic Malignancies Therapeutics Market - France
- 8.4.5.1. France: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.4.5.2. France: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.4.5.3. France: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.6. Hematologic Malignancies Therapeutics Market - Germany
- 8.4.6.1. Germany: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.4.6.2. Germany: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.4.6.3. Germany: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.7. Hematologic Malignancies Therapeutics Market - Italy
- 8.4.7.1. Italy: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.4.7.2. Italy: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.4.7.3. Italy: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.8. Hematologic Malignancies Therapeutics Market - Spain
- 8.4.8.1. Spain: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.4.8.2. Spain: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.4.8.3. Spain: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.9. Hematologic Malignancies Therapeutics Market - Netherlands
- 8.4.9.1. Netherlands: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.4.9.2. Netherlands: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.4.9.3. Netherlands: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.10. Hematologic Malignancies Therapeutics Market - Russia
- 8.4.10.1. Russia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.4.10.2. Russia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.4.10.3. Russia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.11. Hematologic Malignancies Therapeutics Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.4.11.2. Rest of Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.4.11.3. Rest of Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5. Hematologic Malignancies Therapeutics Market - Asia Pacific
- 8.5.1. Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.4. Hematologic Malignancies Therapeutics Market - China
- 8.5.4.1. China: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.5.4.2. China: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.5.4.3. China: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.5. Hematologic Malignancies Therapeutics Market - India
- 8.5.5.1. India: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.5.5.2. India: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.5.5.3. India: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.6. Hematologic Malignancies Therapeutics Market - Malaysia
- 8.5.6.1. Malaysia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.5.6.2. Malaysia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.5.6.3. Malaysia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.7. Hematologic Malignancies Therapeutics Market - Japan
- 8.5.7.1. Japan: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.5.7.2. Japan: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.5.7.3. Japan: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.8. Hematologic Malignancies Therapeutics Market - Indonesia
- 8.5.8.1. Indonesia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.5.8.2. Indonesia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.5.8.3. Indonesia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.9. Hematologic Malignancies Therapeutics Market - South Korea
- 8.5.9.1. South Korea: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.5.9.2. South Korea: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.5.9.3. South Korea: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.10. Hematologic Malignancies Therapeutics Market - Australia
- 8.5.10.1. Australia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.5.10.2. Australia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.5.10.3. Australia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.11. Hematologic Malignancies Therapeutics Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.5.11.2. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.5.11.3. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6. Hematologic Malignancies Therapeutics Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.4. Hematologic Malignancies Therapeutics Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.6.4.2. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.6.4.3. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.5. Hematologic Malignancies Therapeutics Market - UAE
- 8.6.5.1. UAE: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.6.5.2. UAE: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.6.5.3. UAE: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.6. Hematologic Malignancies Therapeutics Market - Israel
- 8.6.6.1. Israel: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.6.6.2. Israel: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.6.6.3. Israel: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.7. Hematologic Malignancies Therapeutics Market - South Africa
- 8.6.7.1. South Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.6.7.2. South Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.6.7.3. South Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.8. Hematologic Malignancies Therapeutics Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.6.8.2. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.6.8.3. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.7. Hematologic Malignancies Therapeutics Market - Latin America
- 8.7.1. Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.7.4. Hematologic Malignancies Therapeutics Market - Mexico
- 8.7.4.1. Mexico: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.7.4.2. Mexico: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.7.4.3. Mexico: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.7.5. Hematologic Malignancies Therapeutics Market - Brazil
- 8.7.5.1. Brazil: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.7.5.2. Brazil: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.7.5.3. Brazil: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.7.6. Hematologic Malignancies Therapeutics Market - Argentina
- 8.7.6.1. Argentina: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.7.6.2. Argentina: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.7.6.3. Argentina: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.7.7. Hematologic Malignancies Therapeutics Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.7.7.2. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.7.7.3. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. AbbVie Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Amgen Inc.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Bristol-Myers Squibb Company
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. F. Hoffmann-La Roche Ltd.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Gilead Sciences Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Johnson & Johnson
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Novartis AG
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Pfizer Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Merck & Co., Inc.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Takeda Pharmaceutical Company Limited
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. AstraZeneca
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. BeiGene
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
- 10.13. Kite Pharma (a subsidiary of Gilead Sciences)
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
- 10.14. Celgene Corporation (acquired by Bristol-Myers Squibb)
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
- 10.15. Regeneron Pharmaceuticals, Inc.
- 10.15.1. Company Overview
- 10.15.2. Financial Performance
- 10.15.3. Product Benchmarking
- 10.15.4. Recent Development
샘플 요청 목록